RxDoctor Payments Data

Laura Bottomley-Brown

Family · Petoskey, MINPI 1568947596

Payments from drug & device makers

$3,999in general payments, 2019–2025

Across 138 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$857
  • Sanofi$588
  • E.r. Squibb & Sons, L.L.C.$489
  • Novartis$483
  • Pfizer$243
  • Amgen$239
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,75694%
  • Education$2436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,999 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$194,581
Medicare patients
950
Services billed
3,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$384,216
Dupixent PenDupilumab23$87,056
OtezlaApremilast12$55,005
Fluorouracil168$10,211
Tacrolimus43$4,501
Calcipotriene18$3,359
Metronidazole43$2,188
Clobetasol Propionate81$1,972
Tretinoin20$1,691
Ketoconazole93$1,462
Betamethasone Dipropionate30$1,075
Triamcinolone Acetonide154$1,024
Ciclopirox23$930
Azelaic Acid16$901
Doxycycline Hyclate42$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$239$55,00512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Petoskey

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →